GlassScriptPhysician profile
Hany Youssef
NPI 1689201840
$1,461.73
in general payments reported to CMS, 2019-2025
11 companies · $483 in 2025
The $483 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.79 · 2021: $80.58 · 2022: $392 · 2023: $240 · 2024: $246 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $365.63 | 2022-2023 | Diamondback Coronary |
| Abiomed | $294.74 | 2025 | |
| Medtronic, INC. | $218.81 | 2022-2025 | Micra |
| Atricure, INC. | $152.50 | 2024 | |
| Pfizer INC. | $95.39 | 2023 | |
| Boston Scientific Corporation | $80.58 | 2021 | |
| Biosense Webster, INC. | $80.44 | 2025 | Soundstar, Na |
| Shockwave Medical, INC | $54.04 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $53.47 | 2023-2024 | Enbrel, Repatha, Otezla |
| Abbvie INC. | $45.13 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $21.00 | 2025 | Lokelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hany Youssef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.